|
BioRelix and Dalton Medicinal Chemistry Sign Research
Agreement to Capitalize on RiboSwitch Technology
NEW HAVEN, CT, and TORONTO, November 13, 2007 /PRNewswire/ -
BioRelix, pioneers in the discovery and development of
RiboSwitch based therapeutic agents and Dalton Medicinal
Chemistry, have jointly announced a research collaboration to
discover new therapeutics.
Dalton Medicinal Chemistry will utilize their proprietary
insights to design and synthesize several novel classes of
compounds against selected RiboSwitch targets. BioRelix will
advance these compounds using their cutting edge battery of
biological assays and thorough knowledge of RiboSwitch drug
discovery and development.
Brian Dixon, BioRelix CEO commented: "We are pleased to have the
opportunity to work with the creative team at Dalton Medicinal
Chemistry in the discovery of new entities for treating
infectious diseases. Their expertise, coupled with our
proprietary and leading position in RiboSwitch technology will
lead to important new medicines."
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We
are delighted to have this opportunity to work with BioRelix in
the discovery of much needed new anti-infective agents. The team
at BioRelix has clearly established an exceptionally innovative
approach to anti-infectives."
About BioRelix
BioRelix Pharmaceuticals, Inc. is a drug discovery and
development company focused on identifying new anti-infective
drug treatments. BioRelix is building a portfolio of
anti-infective products based on novel patented RNA targets,
termed RiboSwitches, which were identified in the laboratory of
BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes
Investigator and Henry Ford II Professor at Yale University.
BioRelix investors include CHL Medical Partners, New Leaf
Venture Partners, Aisling Capital, Novartis Venture Fund, Elm
Street Ventures and Alexandria Real Estate Equities.
About Dalton Pharma Services
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is
a Health Canada approved contract pharmaceutical manufacturer
that supplies chemistry and analytical services to the
biotechnology and pharmaceutical industries in the areas of
chemistry, medicinal chemistry and fine chemical manufacture.
Dalton provides cGMP manufacturing and sterile filling services
to its customers at any stage of the regulatory process (Phase
I, II, III or commercial). In its state of the art cGMP
facilities, Dalton produces active pharmaceutical ingredients at
the gram or kilogram scale. Dalton conducts sterile fills to
produce batches of finished drug product in vials or syringes,
either aseptically filled or terminally sterilized, under fully
validated conditions. In addition, Dalton's analytical chemistry
laboratory offers method development, validation and ICH
stability programs to its clients.
Contact
BioRelix, Inc., Brian R. Dixon, (203) 785-9282,
www.biorelix.com;Dalton Pharma Services, Peter Pekos, (416)
661-2102, www.dalton.com
|
